Is Reata Pharmaceuticals, Inc. overvalued or undervalued?

Jun 25 2025 08:44 AM IST
share
Share Via
As of October 5, 2023, Reata Pharmaceuticals, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 3.1, indicating a solid financial position compared to peers like Amgen and Vertex Pharmaceuticals.
As of 5 October 2023, Reata Pharmaceuticals, Inc. has moved from fair to attractive based on recent analyses. The company is currently undervalued. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 3.1, and a debt-to-equity ratio of 0.4, indicating a solid financial position relative to its earnings and asset base.

In comparison to peers, Amgen Inc. has a price-to-earnings ratio of 18.5, while Vertex Pharmaceuticals boasts a price-to-book ratio of 4.0. This suggests that Reata Pharmaceuticals is trading at a discount compared to its industry counterparts. Additionally, recent stock performance has shown resilience, outperforming the Sensex, which further supports the notion of its undervaluation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
What does Reata Pharmaceuticals, Inc. do?
Jun 22 2025 06:29 PM IST
share
Share Via